Rezolute is a clinical-stage company developing ersodetug, an antibody that dampens insulin's effect, for dangerously low blood sugar caused by tumors or by congenital hyperinsulinism; it is not approved.
Rezolute's case rests on investigational ersodetug for hyperinsulinism. sunRIZE missed its primary and key secondary endpoints in congenital HI, leaving that filing uncertain despite FDA's pre-BLA invitation. Fully enrolled, single-arm upLIFT offers a potential tumor HI route, with topline expected mid-December 2026. Management now guides runway through Q1 2028 and targets a congenital HI BLA in 2027; the filing strategy depends on upLIFT and regulatory discussions. Longer-term funding remains necessary.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: upLIFT confirms ersodetug works in tumor hyperinsulinism
Will the full tumor HI results show convincing reductions in intravenous glucose needs with acceptable safety?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Longer runway supports ersodetug plans; upLIFT and congenital HI filing remain pivotal
Ersodetug's fate hinges on whether FDA accepts CGM-based sunRIZE data and whether upLIFT confirms tumor HI efficacy at full enrollment
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Other cancers, Endocrine and bone diseases, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
vs. direct competitors
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.